MedLife launches the EarlyCDT® test, which allows early detection of lung cancer by identifying specific autoantibodies, available in all its units.
Delia Niculescu
Current Affairs
foto:shutterstock
Always see our news on Google
MedLife Group, the leading private healthcare provider in Romania, has introduced the EarlyCDT® test, a blood-based immunologic test for the early detection of lung cancer. It identifies autoantibodies produced by the body up to 4 years before visible lesions appear. The test is non-invasive and is mainly targeted at people with risk factors, with a turnaround time of about 15 days. Studies show that the use of this test reduces late-stage diagnoses by 36%, increasing the chances of survival. MedLife reaffirms its commitment to innovation in laboratory medicine.
Sources
MedLife introduce în premieră în România testul EarlyCDT®, un test de sânge pentru depistarea timpurie a cancerului pulmonar
Inovație în medicina de laborator: MedLife introduce în premieră în România testul EarlyCDT®, un test de sânge pentru depistarea timpurie a cancerului pulmonar
MedLife introduce în premieră în România testul EarlyCDT®, un test de sânge pentru depistarea timpurie a cancerului pulmonar
Latest News
17:45
The General Staff of Ukraine estimates Russia's losses since the beginning of the invasion at 1.47 million soldiers
17:34
Investigations and accusations of inappropriate behavior against a former deputy director of the Operetta Theater in Bucharest
17:26
A villa on the private island of Isola d'Isca, along the Amalfi Coast, is available for rent at 300,000 euros per week.
17:16
General Alexus Grynkewich led a meeting of NATO defense chiefs regarding security in the Strait of Hormuz
17:04
The Ministry of Defense confirmed the presence of drone fragments with explosive payload in the Tuzla beach area, Constanța County, neutralized by the EOD team.
See more news
NEWS ON THE SAME TOPICS
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
